News | January 27, 2025
Granules India Q3 FY25 PAT drops 6% to Rs 118 Cr
The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations
The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations
Q3 FY25 revenue up 24% to Rs 3,230 crore
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
Morepen Laboratories approves hiving off of medical devices business
According to IQVIA, the European market for Buprenorphine-based opioid dependency treatments in 2023 surpassed USD 355 million annually
Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A
SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage
Subscribe To Our Newsletter & Stay Updated
